Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
23.04.24
18:06 Uhr
189,40 Euro
+1,55
+0,83 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
186,40189,4523.04.
187,20188,4523.04.
PR Newswire
717 Leser
Artikel bewerten:
(2)

Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients

Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle

BARCELONA, Spain, May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, and Syneos Health are among the speakers at Veeva R&D and Quality Summit, June 6-7 in Madrid, Spain. Industry innovators will share how they leverage next-generation solutions to drive efficiencies that help deliver better patient outcomes.

Veeva Systems

Veeva R&D and Quality Summit will bring together more than 750 industry professionals to participate in over 40 sessions. Attendees will learn about strategies for developing the foundation for clinical operations and data in patient-centric trials, elevating quality management beyond compliance, streamlining regulatory processes, and improving oversight and efficiency in safety.

Featured keynotes and panel discussions include:

  • Bayer outlining its regulatory journey to deliver a comprehensive view of approved content for a large and varied product portfolio.
  • Boehringer Ingelheim highlighting its launch of a product development operating system for the future.
  • LEO Pharma discussing the elevated role of safety as a strategic partner in product development.
  • GSK, Recordati, and Syneos Health sharing their respective journeys to improve clinical trials.

"Our top priority is helping the industry deliver innovation that ensures the best possible outcomes for patients," says Rik Van Mol, senior vice president of Veeva Development Cloud. "Veeva R&D and Quality Summit offers industry leaders an ideal forum to connect, exchange ideas, and share strategies that will drive the industry forward."

The event is open exclusively to life sciences professionals. Register and stay up to date on the agenda and program details at veeva.com/eu/Summit.

Additional Information

To register for Veeva R&D and Quality Summit visit: veeva.com/eu/Summit
Learn more about Veeva Development Cloud: veeva.com/eu/DevelopmentCloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/4050205/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-connect-at-veeva-rd-and-quality-summit-to-advance-innovation-for-the-industry-and-patients-301833114.html

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.